Inventiva S.A. (0RNK.L) LSE
3.24
-0.28(-7.97%)
Currency In EUR
- General
- Statistics
- Historical Data
- Profile
- Financials
3.24
-0.28(-7.97%)
Currency In EUR
Sector
Healthcare
Industry
Biotechnology
Employees
114
First IPO Date
March 30, 2017
| Name | Title | Pay | Year Born |
| Andrew Obenshain | Chief Executive Officer | 152,244 | 1975 |
| Martine Zimmermann | Executive VP of Regulatory Affairs & Quality Assurance and Head of Regulatory Affairs | 226,090 | 1969 |
| Jason A. Campagna | President of Research and Development & Chief Medical Officer | 338,177 | 1967 |
| Jean Volatier | Executive VP Finance & Corporate Social Responsibility | 355,566 | 1965 |
| Pierre Broqua | Co-Founder | 411,801 | 1962 |
| Axel-Sven Malkomes | Chief Financial Officer | 0 | 1967 |
| Eric Duranson | General Counsel | 0 | 1974 |
| Nathalie Harroy | Head of Human Resources | 0 | 1967 |
| Nazira Amra | Chief Commercial Strategy Officer | 0 | N/A |
| Pamela Herbster | Chief People Officer | 0 | N/A |
| Pascaline Clerc | Executive Vice President of External and Corporate Affairs | 0 | 1981 |
| Susan Coles | Chief Legal Officer | 0 | 1967 |
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.